ArticleCureus2026
Primary Peritoneal High-Grade Serous Carcinoma Presenting With Diffuse Carcinomatosis and No Ovarian Mass: A Case of Exceptional Response.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary peritoneal serous carcinoma (PPSC) is a rare Müllerian malignancy that closely resembles ovarian carcinoma but is distinguished by minimal or absent ovarian involvement despite extensive peritoneal disease. Diagnosis becomes particularly challenging when no adnexal mass is identified, and in such cases, ascitic fluid cytology with Müllerian immunophenotyping may provide the only definitive diagnostic pathway. We report the case of a 63-year-old woman who presented with worsening abdominal pain, diffuse ascites, and imaging findings consistent with peritoneal carcinomatosis but without an ovarian or pelvic mass. Ascitic fluid cytology repeatedly demonstrated malignant epithelial cells expressing PAX8, CK7, and abnormal p53, confirming Müllerian origin and supporting a diagnosis of PPSC. Serial CA-125 levels rose markedly prior to treatment initiation, reaching 864.8 U/mL. The patient received neoadjuvant chemotherapy with carboplatin, paclitaxel, and bevacizumab, resulting in rapid symptomatic improvement, normalization of CA-125, and complete radiologic resolution of carcinomatosis. She subsequently underwent interval debulking surgery, during which no residual viable carcinoma was identified, consistent with a pathologic complete response. This case illustrates the diagnostic challenges of PPSC in the absence of an adnexal mass and demonstrates the value of ascitic cytology and Müllerian immunoprofiles when tissue biopsy is not feasible. It also highlights the prognostic significance of robust chemotherapy response, as pathologic complete remission remains uncommon in high-grade serous Müllerian carcinomas. Overall, this case underscores the importance of recognizing atypical presentations of PPSC and shows that exceptional therapeutic outcomes are achievable with appropriately selected neoadjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.